pharma news Archives - DelveInsight

pharma news

pharma-biotech-news-updates-for-novartis-boston-scientific-boehringer-ingelheim
Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biote...

Boston Scientific pays USD 336 Million to acquire blood clot medical device firmBoston Scientific Corp. is shelling out as much as USD 336 million to take over the rest of medical device firm ...


pharma-biotech-news-updates-for-biogen-smartlabs-synlogic-partner-therapeutics
Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in...

Win-win for Biogen as its Biosimilar Gets Approval for AMD Samsung Bioepis and Biogen's biosimilar drug, Byooviz, received USFDA approval for the treatment of vision loss, Age-related mac...


pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics
FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges D...

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodi...


recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma
ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy...

ADARx bags USD 75 Million to advance its RNA tech pipelineADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Ser...


pharma-news-updates-for-roche-mayo-clinic-owlstone-transmedics-google
Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic bui...

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 BillionA collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will co...


recent-pharma-news-and-updates-for-Pfizer-Forte-Biosciences- Bone-Therapeutics-Versanis-Bio-AC-Immune
Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthrit...

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a ...


pharma-news-and-updates-for-Ascendis-MicroTransponder-BioMarin-Zimmer-Biomet-Canary-Medical
Ascendis’s SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin’s Voxzogo; Zi...

FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone DeficiencyFor the treatment of growth failure due to deficiency of growth hormones, the USFDA appr...


pharma-happenings-for-roche-allstripes-datavant-bluewillow-shape-therapeutics
Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Pa...

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 BillionSeattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Ro...


recent-pharma-news-updates-for-hebabiz-pfizer-astrazeneca-bms-masimo
AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers S...

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral SclerosisAstraZeneca's 39 billion USD complete a...


pharma-news-updates-for-merck-eisai-fibrogen-jazz-pfizer-ipsen-seagen
FDA approval to Keytruda and Lenvima; FibroGen’s Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palo...

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC)The FDA approved the combination of Keytruda and Lenvima produced by Merck and Ei...


Editor's Pick
Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

Healthcare Data Breach: What it Means for Companies and the Consumer?

Data and analytics today are playing a major role in the organization’s growth. Stakeho...

Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Co...

Onychomycosis is the most commonly prevalent nail infection in adults. It is a fungal i...

Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

The necessity of a robust Angelman syndrome pipeline is indispensable at the current mo...

The New Buzz of Transcranial Stimulation Devices in the Neurological Disorder...

Neurological disorders are one of the major causes of death and disability across the g...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.